209 related articles for article (PubMed ID: 34088712)
1. Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2.
Corsa CAS; Walsh CM; Bagchi DP; Foss Freitas MC; Li Z; Hardij J; Granger K; Mori H; Schill RL; Lewis KT; Maung JN; Azaria RD; Rothberg AE; Oral EA; MacDougald OA
Diabetes; 2021 Sep; 70(9):1970-1984. PubMed ID: 34088712
[TBL] [Abstract][Full Text] [Related]
2. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
[TBL] [Abstract][Full Text] [Related]
3. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
Friesen M; Cowan CA
Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
[TBL] [Abstract][Full Text] [Related]
4. Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning.
Pellegrini C; Columbaro M; Schena E; Prencipe S; Andrenacci D; Iozzo P; Angela Guzzardi M; Capanni C; Mattioli E; Loi M; Araujo-Vilar D; Squarzoni S; Cinti S; Morselli P; Giorgetti A; Zanotti L; Gambineri A; Lattanzi G
Exp Mol Med; 2019 Aug; 51(8):1-17. PubMed ID: 31375660
[TBL] [Abstract][Full Text] [Related]
5. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
[TBL] [Abstract][Full Text] [Related]
6. Itm2a silencing rescues lamin A mediated inhibition of 3T3-L1 adipocyte differentiation.
Davies SJ; Ryan J; O'Connor PBF; Kenny E; Morris D; Baranov PV; O'Connor R; McCarthy TV
Adipocyte; 2017 Oct; 6(4):259-276. PubMed ID: 28872940
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction.
Schena E; Mattioli E; Peres C; Zanotti L; Morselli P; Iozzo P; Guzzardi MA; Bernardini C; Forni M; Nesci S; Caprio M; Cecchetti C; Pagotto U; Gabusi E; Cattini L; Lisignoli G; Blalock W; Gambineri A; Lattanzi G
Cells; 2023 Nov; 12(22):. PubMed ID: 37998321
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
[TBL] [Abstract][Full Text] [Related]
9. Cellular Metabolism and Bioenergetic Function in Human Fibroblasts and Preadipocytes of Type 2 Familial Partial Lipodystrophy.
Algieri C; Bernardini C; Trombetti F; Schena E; Zannoni A; Forni M; Nesci S
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955791
[TBL] [Abstract][Full Text] [Related]
10. Extracellular matrix remodeling and transforming growth factor-β signaling abnormalities induced by lamin A/C variants that cause lipodystrophy.
Le Dour C; Wu W; Béréziat V; Capeau J; Vigouroux C; Worman HJ
J Lipid Res; 2017 Jan; 58(1):151-163. PubMed ID: 27845687
[TBL] [Abstract][Full Text] [Related]
11. Histological and molecular features of lipomatous and nonlipomatous adipose tissue in familial partial lipodystrophy caused by LMNA mutations.
Araújo-Vilar D; Victoria B; González-Méndez B; Barreiro F; Fernández-Rodríguez B; Cereijo R; Gallego-Escuredo JM; Villarroya F; Pañeda-Menéndez A
Clin Endocrinol (Oxf); 2012 Jun; 76(6):816-24. PubMed ID: 21883346
[TBL] [Abstract][Full Text] [Related]
12. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
[TBL] [Abstract][Full Text] [Related]
13. A lipodystrophy-causing lamin A mutant alters conformation and epigenetic regulation of the anti-adipogenic
Oldenburg A; Briand N; Sørensen AL; Cahyani I; Shah A; Moskaug JØ; Collas P
J Cell Biol; 2017 Sep; 216(9):2731-2743. PubMed ID: 28751304
[TBL] [Abstract][Full Text] [Related]
14. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
[TBL] [Abstract][Full Text] [Related]
15. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
Gambineri A; Zanotti L
Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
[TBL] [Abstract][Full Text] [Related]
16. Generation of an integration-free induced pluripotent stem cell line (PUMCHi001-A) from a patient with familial partial lipodystrophy type 2 (FPLD2) carrying a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene.
Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
Stem Cell Res; 2020 Jan; 42():101651. PubMed ID: 31794942
[TBL] [Abstract][Full Text] [Related]
17. Genomic loci mispositioning in Tmem120a knockout mice yields latent lipodystrophy.
Czapiewski R; Batrakou DG; de Las Heras JI; Carter RN; Sivakumar A; Sliwinska M; Dixon CR; Webb S; Lattanzi G; Morton NM; Schirmer EC
Nat Commun; 2022 Jan; 13(1):321. PubMed ID: 35027552
[TBL] [Abstract][Full Text] [Related]
18. Generation of an isogenic gene-corrected iPSC line (PUMCHi001-A-1) from a familial partial lipodystrophy type 2 (FPLD2) patient with a heterozygous R349W mutation in the LMNA gene.
Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
Stem Cell Res; 2020 Apr; 44():101753. PubMed ID: 32213461
[TBL] [Abstract][Full Text] [Related]
19. Irisin levels in LMNA-associated partial lipodystrophies.
Bensmaïne F; Benomar K; Espiard S; Vahe C; Le Mapihan K; Lion G; Lemdani M; Chazard E; Ernst O; Vigouroux C; Pigny P; Vantyghem MC
Diabetes Metab; 2019 Jan; 45(1):67-75. PubMed ID: 30165155
[TBL] [Abstract][Full Text] [Related]
20. Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.
Zhong ZX; Harris J; Wilber E; Gorman S; Savage DB; O'Rahilly S; Stears A; Williams RM
Clin Endocrinol (Oxf); 2022 Dec; 97(6):755-762. PubMed ID: 35920656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
